Axinn Obtains Global Antitrust Clearance for Thermo Fisher Scientific Inc.’s $13.6 billion Acquisition
January 31, 2014
Axinn was global coordinating antitrust counsel to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in its $13.6 billion acquisition of Life Technologies Corporation.
Axinn worked with Slaughter & May to help Thermo Fisher secure global clearance across nine different jurisdictions (Federal Trade Commission, European Commission, PRC’s MOFCOM, Canada, Japan, South Korea, Russia, Australia and New Zealand).
The Axinn and Slaughter & May teams successfully navigated nine regulatory reviews of more than fifty (50) different product areas involving complex life science products, which included a Second Request from the Federal Trade Commission and a Phase II investigation from MOFCOM. Axinn and Slaughter & May secured global convergence on remedies through a single US$1 billion divestiture to General Electric Company (as an upfront buyer), tailored to cover only three product areas, and local supply and pricing remedies in China for two additional product areas.
The Axinn team included partners John Harkrider, Michael Keeley, Mark Alexander and Daniel Bitton; counsel Morris Bloom; and associate Daniel Oakes.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
New Frontiers of Antitrust – 16th Annual International Conference of Concurrences Review
Speaking Engagement
Antitrust
GCR Live Global: Navigating the Future of Antitrust 2026
Speaking Engagement
Antitrust
Stakeholders 25th Annual CYOC Career Development Conference
Sponsorship
Antitrust
American Investment Council’s General Counsel Day
Speaking Engagement
Antitrust
Informa 34th Annual Advanced EU Brussels Conference
Speaking Engagement
Antitrust
Kisaco Research Pharma and Biotech Patent Litigation Summit 2025
Speaking Engagement
Intellectual Property
GCR Live: Women in Antitrust 2025
Speaking Engagement
Antitrust
Global Legal Group Global Class Actions Symposium 2025
Speaking Engagement
Litigation & Trials
Biosimilar Approval Pathway Changes Sponsors Need to Monitor
Media Mentions
Intellectual Property